Seres Therapeutics (MCRB) Share-based Compensation (2014 - 2026)

Seres Therapeutics has reported Share-based Compensation for 13 years, with the latest figure at $1.8 million in Q1 2026.

• Quarterly Share-based Compensation fell 37.35% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 106.09% YoY) and the FY2025 annual result came in at $10.0 million, down 52.38% from the prior year.
• Share-based Compensation grew to $1.8 million in Q1 2026 per MCRB's latest filing, from -$7.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $73.2 million in Q4 2022 and troughed at -$7.6 million in Q4 2025.
• A 5-year average of $8.7 million and a median of $5.2 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 375.99% in 2022, then slumped 302.95% in 2025.
• Over 5 years, Share-based Compensation stood at $73.2 million in 2022, then slumped by 93.05% to $5.1 million in 2023, then retreated by 25.97% to $3.8 million in 2024, then plunged by 302.95% to -$7.6 million in 2025, then surged by 123.11% to $1.8 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.8 million, -$7.6 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.